Silence Therapeutics (SLN) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$122.4 million.
- Silence Therapeutics' Enterprise Value fell 5200.97% to -$122.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.4 million, marking a year-over-year decrease of 5200.97%. This contributed to the annual value of -$147.3 million for FY2024, which is 11970.25% down from last year.
- Per Silence Therapeutics' latest filing, its Enterprise Value stood at -$122.4 million for Q3 2025, which was down 5200.97% from -$186.6 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Enterprise Value ranged from a high of -$37.2 million in Q2 2023 and a low of -$208.1 million during Q1 2025
- Its 5-year average for Enterprise Value is -$102.0 million, with a median of -$98.5 million in 2021.
- Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 67688.26% in 2021, then soared by 4272.79% in 2023.
- Over the past 5 years, Silence Therapeutics' Enterprise Value (Quarter) stood at -$99.1 million in 2021, then surged by 35.14% to -$64.3 million in 2022, then dropped by 4.3% to -$67.1 million in 2023, then crashed by 119.7% to -$147.3 million in 2024, then grew by 16.95% to -$122.4 million in 2025.
- Its last three reported values are -$122.4 million in Q3 2025, -$186.6 million for Q2 2025, and -$208.1 million during Q1 2025.